Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist
According to the Canadian Adult Obesity Clinical Practice Guidelines, drug therapy for weight management is appropriate for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity
[CrossRef] [PubMed] [Google Scholar] The evolution of technology and physical inactivity: The good, the bad, and the way forward
Some patients are naturally more responsive to GLP-1 receptor agonists than others due to various physiological factors
While it is still not FDA-approved, it is being clinically tested and studied as a solution for obesity
US$ 29.95
US$ 20.68
US$ 24.64
